THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Amgen delivered a strong fourth quarter of 2025 and looks well-positioned to absorb the LOEs on Prolia, Xgeva, and Ravicti in ...
How Does Repatha Work for High Cholesterol? People can have high cholesterol for a number of reasons, including their diet, exercise habits, or genetic conditions. Keeping your cholesterol low, ...
Stocktwits on MSN
Amgen CEO teases 2026 as ‘springboard year’ after 14 blockbusters and 18 record products
Amgen’s financial performance was underpinned by strength in its lineup. The company said 14 products generated at least $1 billion each in annual sales, 13 posted double-digit growth, and 18 ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Amgen Inc (AMGN) reports robust sales growth with 14 blockbuster products, while navigating competitive pressures and strategic pivots.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results